Empagliflozin in Patients with Chronic Kidney Disease
TEThe EMPA-KIDNEY Collaborative Group
Indexed incrossrefpubmed
Abstract
Background
The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
Methods
, a sustained decrease in eGFR of ≥40% from baseline, or death from renal causes) or death from cardiovascular causes.
Citation impact
2,339
total citations
- FWCI
- 275.55
- Percentile
- 100%
- References
- 26
Citations per year
Authors
1- TEThe EMPA-KIDNEY Collaborative GroupCorresponding
Topics & keywords
Topics
Keywords
- Empagliflozin
- Medicine
- Kidney disease
- Disease
- EMPA
- Internal medicine
- Intensive care medicine
- Diabetes mellitus
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.